News

Nanotechnology Paves the Way for Next-Generation Skin Cancer Treatments

Leave a Comment / Technology Innovation /

Skin cancer includes melanoma (MSC) and non-melanoma types (NMSC) such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Melanoma is less common but more deadly, with about 324,000 new cases and 57,000 deaths annually. NMSCs are far more common, especially BCC, though SCC causes most related deaths. Conventional treatments like surgery, radiation, chemotherapy, […]

Nanotechnology Paves the Way for Next-Generation Skin Cancer Treatments Read More »

Cadonilimab Plus Chemotherapy Extends Survival in Advanced Gastric and GEJ Cancer, Phase 3 Trial Confirms

Leave a Comment / Treatment /

The final results of the Phase 3 COMPASSION-15 trial confirmed that cadonilimab, a bispecific PD-1/CTLA-4 antibody, combined with XELOX chemotherapy offers a significant long-term survival benefit for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma compared to XELOX alone. After a median follow-up of 33.9 months, patients treated with cadonilimab plus XELOX achieved a

Cadonilimab Plus Chemotherapy Extends Survival in Advanced Gastric and GEJ Cancer, Phase 3 Trial Confirms Read More »

FDA Approves Y-90 Microspheres for Unresectable Liver Cancer with 98.5% Response Rate

Leave a Comment / Drug Approvals /

The FDA has approved SIR-Spheres Y-90 resin microspheres for treating patients with unresectable hepatocellular carcinoma (HCC) who meet specific clinical criteria, such as no macrovascular invasion, Child-Pugh A cirrhosis, and well-compensated liver function. The approval is supported by the DOORwaY90 study, a multicenter trial evaluating Y-90 as a first-line therapy for unresectable HCC. Results were

FDA Approves Y-90 Microspheres for Unresectable Liver Cancer with 98.5% Response Rate Read More »

Scientists Uncover RNA-Driven Mechanism Behind Rare Kidney Cancer

Research Advances /

Scientists have uncovered how a rare and aggressive kidney cancer, translocation renal cell carcinoma (tRCC), develops. This cancer, mainly affecting children and young adults, is caused by abnormal hybrid genes called TFE3 oncofusions. These genes hijack the cell’s machinery to form liquid-like structures, or “droplet hubs,” inside the nucleus. RNA, instead of only carrying genetic

Scientists Uncover RNA-Driven Mechanism Behind Rare Kidney Cancer Read More »

CAR T-Cell Therapies Redefine Treatment for Relapsed Large B-Cell Lymphoma

Leave a Comment / Immunotherapy /

A new treatment era has begun for patients with relapsed or refractory large B-cell lymphoma (LBCL) following the FDA approval of the CAR T-cell therapies axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel (Breyanzi). Both therapies have proven superior to the previous standard treatment of salvage chemotherapy followed by transplant. In major clinical trials, axi-cel showed a

CAR T-Cell Therapies Redefine Treatment for Relapsed Large B-Cell Lymphoma Read More »

Targeted Drug Combo Slows Progression of Advanced Prostate Cancer with BRCA Mutations

Leave a Comment / Treatment /

Researchers found that adding the targeted drug niraparib to standard treatment (abiraterone acetate and prednisone) significantly slows the progression of advanced prostate cancer in men with specific DNA repair gene mutations. The trial included 696 men whose cancer had spread and who carried Homologous Recombination Repair (HRR) gene mutations, such as BRCA1 or BRCA2. The combination therapy reduced

Targeted Drug Combo Slows Progression of Advanced Prostate Cancer with BRCA Mutations Read More »

Early Use of Vitamin B3 Supplement Greatly Reduces Risk of New Skin Cancers

Leave a Comment / Research Advances /

A large U.S. veterans study confirms that nicotinamide, a form of vitamin B3, reduces the risk of new skin cancers. Researchers analyzed 33,833 patients taking 500 mg twice daily for over 30 days versus non-users. Overall, nicotinamide lowered the risk of basal cell carcinoma and squamous cell carcinoma by 14%. The benefit was strongest—about 54%

Early Use of Vitamin B3 Supplement Greatly Reduces Risk of New Skin Cancers Read More »

FDA Accepts Application for XS003, a Lower-Dose Biosimilar of Leukemia Drug

Leave a Comment / Drug Approvals /

The FDA has accepted an application for XS003, a new biosimilar of nilotinib (Tasigna), a standard treatment for chronic myeloid leukemia (CML). Developed by Xspray Pharma using its proprietary HyNap technology, XS003 is designed to improve upon the original drug’s formulation and patient convenience. Clinical data show that XS003 achieves bioequivalence to nilotinib at less

FDA Accepts Application for XS003, a Lower-Dose Biosimilar of Leukemia Drug Read More »

Major Advances in Targeted Therapies Transform Treatment for Blood Cancers

Leave a Comment / Targeted Therapy /

There have been major advances in targeted therapies for blood cancers, especially chronic lymphocytic leukemia (CLL), large B-cell lymphoma (LBCL), and myelofibrosis (MF). In CLL, treatment has largely shifted from chemotherapy to BTK inhibitors. Newer drugs like acalabrutinib (Calquence) and zanubrutinib (Brukinsa) provide strong, lasting responses with fewer side effects than older drugs such as

Major Advances in Targeted Therapies Transform Treatment for Blood Cancers Read More »

Early Detection Offers Hope Against Deadly Pancreatic Cancer

Diagnostics /

Pancreatic cancer is the 12th most common cancer worldwide but has the sixth-highest death rate. Early detection is crucial because survival drops sharply with disease progression: localized cancer has a 44% five-year survival rate, compared with 16% for regional disease and only 3% for distant disease. Unfortunately, fewer than one in seven cases are diagnosed

Early Detection Offers Hope Against Deadly Pancreatic Cancer Read More »